Month: 2026-03

HONG KONG, Mar 27, 2026 - (ACN Newswire) - Analogue Holdings Limited (“Analogue” or the “Company”, together with its subsidiaries, the “Group”) (stock code: 1977), a leading provider of electrical and mechanical (“E&M”) engineering solutions, and information and communications technology services for smart cities, today announced its annual results for the year ended 31 December 2025 (“the Year” or “FY2025”) with net profit growth, contracts-in-hand achieving another record high and order intake more than doubled, providing a solid business foundation for the coming three years and beyond.Financial Highlights- Profit attributable to owners of the Company increased 23.5% to HK$167.0 million.- Contracts-in-hand surged 61.8% to HK$17,878.7 million, hitting another record-high, made possible by a 113.7% increase in order intake to HK$12,913.6 million during the Year.- The intake of new maintenance contracts for housing programmes, environmental projects and lifts and escalators increased 51.4% to HK$1,669 million, reinforcing the recurring revenue stream.- The Group maintained a strong cash position, with bank balances and cash of HK$1,020.8 million and gearing ratio reduced to 10.1% for FY2025 from 26.2%.- The Board has resolved to pay a second interim dividend of HK2.9 cents per share. Total dividend for the year amounted to HK5.5 cents per share with 25.6% increment year-on-year.Chairman Dr Mak Kin Wah said, “The Year 2025 saw profound changes around the world, with challenges and yet also opportunities. Our Group has continued to stride forward: upholding what we commit by delivering the fundamentals well, striving for continuous improvement to make transformation actionable, investing in technology advancement and productivity, and bringing Hong Kong’s engineering excellence to the world. We are pleased to report that the Group achieved profit growth, secured a record level of contracts-in-hand, and continued to build on our international market presence. These accomplishments highlight our distinctive comprehensive capability across diverse business segments, our commitment to excellence, and our leadership in advanced engineering techniques.”“Supported by strong cashflow, we are in a strong position to take on additional work where appropriate and to seize high-value opportunities as they arise. We will continue to stay agile and focused on capturing opportunities across our broad portfolio, build on our competitive strengths through continuous improvement, and reinforce the use of innovative solutions that enhance quality, safety and performance. We remain steadfast in our commitment to our customers, recognising that this is fundamental to earning their trust and cultivating enduring, strategic partnerships. Guided by our motto – ‘We Commit. We Perform. We Deliver’ – we will continue to maximise value for customers, shareholders, suppliers and stakeholders, while contributing to the communities we serve.”Business Review: Building Services- This segment remains the largest revenue contributor, with revenue reaching HK$3,279 million.- Contracts-in-hand reached a record-high level of HK$8,297 million with the total value of new contracts secured in FY2025 doubled to HK$6,470 million. The Group’s competitive edge in multidisciplinary packaged projects and its industry leadership in innovative MiMEP and other new engineering techniques helped it to secure major contracts.- With strategic investments to accelerate innovation and modern manufacturing facilities in Zhuhai and Hong Kong, the Group continues to lead in MiMEP and DfMA technologies.- Following the successful acquisition of a property management licence, the Group expanded its business to deliver integrated solutions across the entire building lifecycle. This new capability, spanning construction, maintenance, operations and long-term facility management, creates a potential revenue stream that complements core services.- Through continuous development of innovative technologies and operational optimisation, the segment is positioning itself to maintain the market competitiveness while exploring opportunities in other markets in Southeast Asia.Environmental Engineering- This segment achieved record-high contracts-in-hand and order intake, increasing 86.9% and 253.7% to HK$8,094 million and HK$5,355 million respectively. Segment revenue also increased by 18.0% year-on-year to HK$1,591 million.- The segment maintained active tendering throughout the period and was awarded significant contracts, including contracts of a record-breaking value to relocate sewage treatment works in Sha Tin to caverns, sewage pumping station at Ma On Shan and more.- Formed a joint venture company in Qingyang city to explore the operation and maintenance business in the Chinese Mainland.- Explored project opportunities in Asia and the Middle East and the expansion of its expert services into Europe.Information, Communications and Building Technologies (“ICBT”)- Segment revenue remained at HK$630 million. Contracts-in-hand totalled HK$852 million at the year end, and order intake was HK$523 million during the Year.- This segment continued to reinforce its leadership in green and intelligent building solutions under the DigiFusion brand, to enable the development of smarter, more sustainable urban environments.- Continued to leverage ATAL Tower as a platform for developing innovative technologies and broaden its technological capabilities through strategic collaborations with leading manufacturers in the Chinese Mainland and around the world, to strengthen its ability to deliver scalable, high-performance solutions across a wide range of sectors.Lifts and Escalators- Revenue and order intake increased 11.0% to HK$587 million and by 3.2% to HK$566 million respectively.- Transel Elevator & Electric Inc. (TEI), the associate company in the United States (US), secured a contract for the world-class vertical transportation system in the iconic 56-storey luxury hotel skyscraper on the border of Times Square in New York. TEI also further strengthened its market position by extending its footprint into the Southeastern part of US.- Actively built on its presence in the UK and broadened its network across other international markets, reinforcing its global ambitions in vertical transportation solutions.- Machine-Room-Less lift products continued to gain traction in key international markets- Streamlined the manufacturing processes of Nanjing factory, broadened its product portfolio and strengthened the overall product quality, aligning with the Group’s global vision and reaffirming its commitment to delivering reliable, high-performance vertical transportation solutions.For further details of the 2025 Annual Results, please refer to the announcement filed with The Stock Exchange of Hong Kong Limited.About Analogue Holdings LimitedEstablished in 1977, Analogue Holdings Limited is a leading provider of electrical and mechanical (“E&M”) engineering solutions and information and communications technology (“ICT”) services for smart cities, with headquarters in Hong Kong and operations in the Chinese Mainland, Macau, the United States, the United Kingdom, Germany, Singapore and Malaysia. Serving a wide spectrum of customers from public and private sectors, the Group provides multidisciplinary and comprehensive E&M engineering and technology services in four major segments, including Building Services, Environmental Engineering, Information, Communications and Building Technologies (“ICBT”) and Lifts & Escalators.The Group also manufactures and sells lifts and escalators internationally and has entered into an alliance with Transel Elevator & Electric Inc. (“TEI”), one of the largest independent lifts and escalators companies in New York, the United States. The Group’s associate partner, Nanjing Canatal Data-Centre Environmental Tech Co., Ltd. (603912.SS), specialises in manufacturing of precision air conditioners. Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com

RESULTS HIGHLIGHTS:- The Revenue for the year ended 31 December 2025 was approximately HK$3,736.5 million, representing an increase of approximately 11.1% as compared with the same period last year.- The Gross Profit Margin for the year ended 31 December 2025 was approximately 55.8%; the gross profit was approximately HK$2,085.0 million, representing an increase of approximately 15.9% as compared with the same period last year.- The Group’s EBITDA for the year ended 31 December 2025 was approximately HK$938.1 million, representing an increase of approximately 32.4% as compared with the same period last year.- The Group’s net profit for the year ended 31 December 2025 was approximately HK$601.2 million, representing an increase of approximately 47.7% as compared with the same period last year.- Basic earnings per share for the year ended 31 December 2025 amounted to approximately HK63.7 cents, representing an increase of approximately 47.5% as compared with the same period last year.- The Board recommended the payment of a final dividend of HK15.0 cents per ordinary share for the year ended 31 December 2025.- For the year ended 31 December 2025, the Group recorded approximately 1,039,000 cases digital solution cases produced from the Group’s production facilities in Mainland China, Thailand and Vietnam, reflecting an increase of 32.7% as compared with the same period in 2024 as a result of our clients’ continued adoption of intra-oral scanners.HONG KONG, Mar 27, 2026 - (ACN Newswire) - 26 March 2026, Modern Dental Group Limited (“Modern Dental” or “the Group”, stock code: 03600.HK), a leading global dental prosthetic device provider, announces its annual results for the year ended 31 December 2025 (“the year”).During the year ended 31 December 2025, the Group’s multi-dimensional strategies and continuous enhancement of operational efficiency and productivity as supported by the ongoing trend of digitalization in the dental industry have resulted in the Group reporting record revenues, net profit and EBITDA numbers during this period. This occurred in a period of challenging macro-economic environment with general softness in demand for dental procedures and trade war uncertainties. The Group has been proactive in its approach to deal with the unprecedented international trade environment leveraging its international production facilities located in Thailand, Vietnam and Mainland China.The global digitalization trend continues to drive consolidation within the dental prosthetics industry, enabling the Group to further expand its market share. Our ongoing digital transformation initiatives are enhancing both customer and patient experiences while improving operational efficiency, further differentiating the Group from competitors and positioning us to outperform industry peers. The Group’s underlying fundamentals remain solid, and we are well positioned to capitalize on emerging opportunities going forward.European BusinessesDuring the year ended 31 December 2025, the European market recorded a revenue of approximately HK$1,887.0 million, representing an increase of approximately HK$268.0 million as compared with the year ended 31 December 2024. This geographic market accounted for 50.5% of the Group’s total revenue. The increase of revenue from the European market was mainly attributable to the increase in sales order volume driven by the launch of new products, such as digital dentures, and our state-of-the-art digital workflows.The Group has been the frontrunner to provide comprehensive digital solutions offerings, ranging from numerous minimal invasive and aesthetic prosthetic solutions to intra-oral scanners and clear aligners, and is well positioned to capture the opportunities arising from the accelerated digitalization trend of the dental industry. The Group continues to aggressively gain market share from international and domestic competitors through our established dental ecosystem solutions with a focus on education and digitalization, which is available within close proximity to our clients; effectively meeting our clients’ high expectations through our various onshore and offshore resources. The Group is committed and will continue to equip ourselves to provide the state-of-the-art digital solutions offerings to the dental community in the market.North American BusinessesDuring the year ended 31 December 2025, the North American market recorded a revenue of approximately HK$696.4 million, representing a decrease of approximately HK$55.7 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 18.6% of the Group’s total revenue.A significant portion of our business in the North America region comprises higher-end products manufactured domestically by MicroDental Laboratories, Inc. and its subsidiaries (“MicroDental Group”). While demand for discretionary cosmetic treatments remained soft throughout 2025, our centralized digital workflows and network-wide production oversight enabled us to deliver enhanced service quality and operational efficiencies to our North American customers.Our diversified supply bases in the US, China, Vietnam and Thailand continue to provide greater flexibility to navigate US tariff uncertainties — an advantage that sets us apart from competitors. Although digitalization of imported product lines drove growth in mass market cases, implementation of the US tariff in April 2025 introduced new uncertainties and contributed to a slow growth in sales for our import-focused business unit.Greater China BusinessesFor the year ended 31 December 2025, the Greater China market recorded a revenue of approximately HK$615.4 million, representing a decrease of approximately HK$46.8 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 16.5% of the Group’s total revenue.The Mainland China market faced headwinds from the volume-based procurement policies and a prolonged period of intense price competition and the situation started to stabilize in the second half of 2025. This also led to aggressive promotions for dental implant treatments by Mainland China dental clinics in Hong Kong (which experienced a notable decrease in patient visits in Hong Kong). The Group’s has deliberately pivoted away from low-margin segments and stay focused on serving mid- and high-value customers, ensuring long-term sustainable profitability of the Group’s business.The Group is optimistic in its mid/long-term outlook for this market in particular where the latest procurement-related government measures are expected to (i) standardize the pricing of dental prosthetics and develop price transparency, which would level the playing field; (ii) allow the Group’s leading brand name and reputation to be a key consideration for its client and customer; and (iii) have the Group benefit from its large production team and its ability to allocate resources efficiently according to the customer or client.Australian BusinessesFor the year ended 31 December 2025, the Australian market recorded a revenue of approximately HK$289.1 million, representing an increase of approximately HK$24.4 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 7.7% of the Group’s total revenue. The increase in revenue from Australia reflected a strong uptake of new digital products driven by the digitalization trend in dental industry and the revenue contribution from the acquisition of Digital Sleep which is partially offset by the depreciation of AUD against HK$ by 2.4% compared with the year ended 31 December 2024.Through our various brands, which offer onshore-and offshore-made products, at multiple price points ranging from economy and standard to premium/boutique, the Group is able to effectively penetrate the entire Australian market. We have invested in local production capacity to provide faster service to our customers, and to provide choices around where the products are made. The Group is one of the largest players in the Australian market and is a preferred supplier to the major corporate dental groups in the market.Other MarketsOther markets primarily include Thailand, Indian Ocean countries, Malaysia, Taiwan and Singapore. For the year ended 31 December 2025, these markets recorded a revenue of approximately HK$248.9 million, representing an increase of approximately HK$182.4 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 6.7% of the Group’s total revenue. The increase in revenue from Other markets was primarily driven by the revenue contribution from the newly acquired Hexa Ceram.Future Prospects and StrategiesThe global macroeconomic environment remains uncertain, with geopolitical tensions and potential tariff changes continuing to create headwinds. However, the Group’s geographically diversified production footprint and global distribution network position us strongly to navigate these challenges. Unlike many competitors reliant on single-country manufacturing, our operations across China, Vietnam and Thailand (including the newly acquired Hexa Ceram) provide superior resilience and flexibility. This strategy, combined with our ability to adapt quickly to local market conditions, enables the Group to mitigate risks and capitalize on opportunities across regions.The dental industry has continued to demonstrate remarkable resilience, underpinned by irreversible demographic trends, including aging populations and increasing awareness of oral health, which drive consistent long-term demand. Building on our record 2025 performance, the Group is well placed to sustain momentum and further strengthen its market leadership.Digitalization remains an irreversible industry trend that is accelerating consolidation of the dental prosthetics industry. We are at the forefront of this transformation, with digital solution cases now representing approximately 35–40% of total volume. Our centralized digital workflows, intra-oral scanner partnerships, proprietary solutions and global education centers have enhanced operational efficiency, reduced turnaround times and delivered superior customer experiences. These initiatives create high entry barriers and will continue to drive margin expansion and market share gains in the coming years.Following the successful integration of Hexa Ceram (Thailand’s largest dental laboratory, acquired in January 2025) and Digital Sleep Design (Proprietary nylon oral appliance to treat obstructive sleep apnea), our Southeast Asian presence and specialized capabilities have been significantly strengthened. This expansion, coupled with our diversified supply bases in the US, China, Vietnam, and Thailand, provides enhanced flexibility to address potential trade and geopolitical risks while supporting faster regional delivery.Looking ahead, the Group remains committed to reinforcing its worldwide leading position through a multi-dimensional approach. We will continue to pursue selective acquisitions, joint ventures and partnerships to expand and complement our product offerings, particularly in our high-growth clear aligner, Trioclear, while strengthening our distribution and sales networks. Ongoing investments in mass-scale production facilities, AI, automation, research and development, and digital innovation will drive efficiency gains and secure our position at the forefront of the industry.About Modern Dental GroupModern Dental Group Limited (Stock code: 03600.HK) is a leading global dental prosthetics provider, distributor and consultant with a focus on providing custom-made prostheses to customers in the growing prosthetics industry. Our product portfolio is broadly categorized into three product lines: fixed prosthetic devices, such as crowns and bridges; removable prosthetic devices, such as removable dentures; and other devices, such as orthodontic devices, sports guards, clear aligners, and anti-snoring devices. Modern Dental Group has a global portfolio of respected brands, including Labocast, Permadental and Elysee Dental in Western Europe, YZJ Dental in China, Modern Dental Lab in Hong Kong, Modern Dental USA and MicroDental in the United States, Modern Dental Pacific in Australia and New Zealand, Modern Dental SG in Singapore, Modern Dental TW in Taiwan, Apex Digital Dental in Malaysia and Hexa Ceram in Thailand. We have grown these brands by providing premium and consistent quality products and superior customer service. We have more than 80 service centers in over 28 countries and serve over 35,000 customers. Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com

HIGHLIGHTS:- Total gross billings amounted to approximately RMB3,955.0 million, representing an increase of approximately 12.8% from approximately RMB3,505.9 million for the corresponding period.- Total revenue was approximately RMB3,430.1 million, representing an increase of approximately 48.7% from approximately RMB2,306.0 million for the corresponding period.- The profit attributable to Shareholders of the Group was approximately RMB921.8 million, representing an increase of approximately 238.5% from approximately RMB272.4 million for the corresponding period.- Non-HKFRS adjusted profit for the year (excluding the share-based compensation expenses) was approximately RMB1,022.5 million, representing an increase of approximately 191.8% from approximately RMB350.5 million for the corresponding period.- Taking into account the financial and cash flow positions of the Group, the Board recommends the payment of a final dividend of approximately HKD168.5 million for the year ended December 31, 2025, representing HKD0.36 per share (in cash), and the proposed final dividend is subject to consideration and approval by Shareholders at the AGM.HONG KONG, Mar 27, 2026 - (ACN Newswire) - JF SmartInvest Holdings Ltd (the “Company” ; together with its subsidiaries, the "Group" or “we”) is pleased to announce its consolidated annual results for the year ended December 31, 2025 (the “Reporting Period”). During the Reporting Period, leveraging its “technology + investment research” dual-drive strategy, the Group achieved outstanding performance. Supported by robust cash flow and profitability, the Board has proposed a final dividend of HK$0.36 per share, bringing the total dividend for the full year to approximately HK$407.4 million when combined with the interim dividend already paid, reflecting its commitment to delivering returns to shareholders.Strong Financial Performance with Substantial Profitability ImprovementDuring the Reporting Period, the Group continued to advance product innovation, AI applications, and investment research capabilities, driving solid growth across its business. Total revenue for the year reached RMB3,430.1 million, representing a YOY increase of 48.7%. Gross profit amounted to RMB2,821.0 million, up 48.9% YOY, while the gross profit margin remained at a high level of 82.2%, indicating the favourable economies of scale and earnings quality of the Group’s business model.In terms of profitability, profit attributable to equity shareholders surged by 238.5% YOY to RMB921.8 million. Excluding share-based compensation expenses, non-HKFRS adjusted profit for the year reached RMB1,022.5 million, representing a YOY increase of 191.8%, fully demonstrating the effective strategy execution and market adaptability of the Group.The Group places great emphasis on shareholder returns. The Board recommends the payment of a final dividend of approximately HKD168.5 million for the year ended December 31, 2025, representing HKD0.36 per share (in cash). Together with the interim dividend of approximately HK$238.9 million already distributed, the total dividend for 2025 will amount to approximately HK$407.4 million. The steady dividend policy fully reflects the Group’s ample cash reserves and its firm confidence in future development prospects.Continued Optimisation of Product Matrix and Enhancement of Diversified Service SystemDuring the Reporting Period, the Group continued to build a diversified product matrix, enriching its product portfolio in response to different customer needs. VIP products 'Stock Navigator, Super Investor' were steadily optimized, with the addition of several quantitative products and AI-powered products. We also launched a 24/7 AI intelligent customer service system, which significantly improved service efficiency. The live streaming system was upgraded, with sessions increasing by 36% YOY and average daily unique viewers exceeding 100,000.Relying on an integrated “AI + content + service + tools” solution, the Enjoy-Stock Pad recorded net sales volume exceeding 75,000 units during the Reporting Period. The Jiuyao Stocks launched over 80 lightweight products, converting professional investment research capabilities into standardised products. The SmartInvest APP completed its strategic transformation from a tool to a platform, with monthly active users increasing by more than 40% YOY and the 30-day retention rate remaining above 50%.The Group further enhanced its product matrix with two new products, Decision Master and Star-tier Services, filling the gap in the mid-tier product system and enabling a seamless trading service experience. Decision Master focuses on three AI+ investment research modules - themes, value investing and quantification - comprehensively enhances investment decision-making capabilities of individual investors. Star-tier Services collaborates with multiple securities brokerages and partners to create a fully integrated closed-loop ecosystem of“tools-services-trading”, serving over 50,000 users during the Reporting Period.Guided by Technological Innovation, Striving Towards “Investment Advisory Intelligent Agent 2.0”The Group regards innovation and technological R&D as its core driving force, accelerating its transformation towards “digital intelligence”, and advancing towards the era of “investment advisory intelligent agent 2.0”. During the Reporting Period, R&D expenses amounted to approximately RMB356 million, with R&D personnel reaching 624, a YOY increase of approximately 42.8%. The Group held 158 software copyrights and patents in AI, big data and product features, with 22 new items added on a year-on-year basis.The self-developed FinSphere Agent Large Model Assistant V3.0 passed the Large Model Assistant Functionality Completeness Test conducted by the China Academy of Information and Communications Technology, becoming the first large-model application in the securities industry. During the Reporting Period, it served approximately 664,000 customers with cumulative services of 22.58 million. The digital intelligent investment robo-advisor “Jiu Ge” served approximately 600,000 customers with cumulative services exceeding 19 million. The Group also launched stock diagnosis intelligent agent 4.0, AI Xiaoce Q&A assistant, and established an intelligent compliance and risk control platform covering the entire business workflow, indicating that the group's AI capabilities have gradually been implemented in core scenarios.To strengthen its technological foundation, the Group established a technology subsidiary, Jiufang Zhiqing, and set its foothold in “Shanghai Foundation Model Innovation Center”, China’s first large model innovation ecosystem community. The subsidiary serves as the Group’s core AI vehicle for operating a native service technology system, promoting the deep application of AI in scenarios such as investment research, investor education, and risk control.Deep-Rooted Investment Research as the Cornerstone, Adhering to Buyer-Side Advisory and Deepening the “1+N” Investment Research SystemThe Group continues to deepen its “1 research institute and N business lines” investment research system, with the JF Financial Research Institute as investment research hub. The Institute has established a pyramidal-structured professional talent echelon led by Chief Economist Dr. Xiao Lisheng, comprising 4 experts, 8 super-IPs and 128 professionals. As of the end of the Reporting Period, the Group had 576 employees holding securities investment advisory qualifications and 2,628 employees holding securities practitioners, maintains a leading team scale and structure in the industry.During the Reporting Period, The Institute conducted more than 300 research activities, covering more than 2,000 listed companies. The Institute authored approximately 1,200 in-depth research reports and 45 sets of thematic courses with a total duration of 2,000 minutes, continuously enhancing the professional capabilities of buyer-side consultants.Multi-Dimensional, Full-Funnel Traffic Operation to Unlock New Growth DimensionsDriven by AI technology, the Group positions refined MCN-based traffic operations as a central hub connecting users with its business, building an integrated, synergistic omni-channel traffic ecosystem comprising “public-domain MCN (multi-platform) + private-domain + proprietary APP”. On the technological front, the Group applied AIGC to restructure content production, shifting from manual creation to “human-machine collaboration” model, and established a data flywheel integrating “advertising data, model training and operational automation”. During the Reporting Period, the Group consolidated its leading position on online short-video and live streaming platforms’ operations, established a multi-platform coordinated traffic matrix, and developed a multi-tiered, high-quality content ecosystem. It also pioneered e-commerce models for the Enjoy-Stock Pad and AppStore models for the APP, driving deep integration between traffic operations and product features.Future OutlookMr. Chen Wenbin, chairman of the Board and chief executive officer of JF SmartInvest Holdings Ltd, said: “In 2025, we remained committed to the dual-drive strategy of ‘technology + investment research’. Not only did we achieve leapfrog growth in performance, but we also successfully led the industry into the era of ‘Investment Advisor Agent 2.0’. Leveraging artificial intelligence and big data technologies, we developed AI products such as the JF Robo-Advisor, FinSphere Agent and FinSphere Report, achieving industry-leading innovations and scenario-based applications, helping users accomplish the critical transition from ‘cognitive improvement’ to ‘decision optimisation’. At the same time, we transformed our professional investment research capabilities into easily accessible lightweight services, realising a strategic shift ‘from tool to platform’. We uphold the principles of rational investing, value investing and long-term investing, assisting clients in developing sound investment philosophies.“In the future, the Group will focus on four key strategic dimensions. First, deepening AI-driven empowerment across all scenarios, accelerating the iteration of AI agents and their commercialisation on the consumer side, and driving the Group’s digital and intelligent transformation. Second, leveraging Forthright Securities and Forthright Capital’s licenses, advancing the globalisation strategy by exporting the Jiufang’s core models, accelerating overseas business expansion. Meanwhile, promoting license upgrading and strategic investment layout to further improve the construction of digital asset infrastructure. Third, strengthening product-driven business diversification and synergies, deepening cooperation with licensed financial institutions such as securities brokerages, and building a service closed loop covering pre-investment, in-investment and post-investment. Fourth, continuing to optimize the customer operation system, unlocking the value of traffic through full-funnel traffic initiatives, and achieving long-term customer retention. We are dedicated to making investing simpler and more professional while enhancing investors’ sense of fulfillment in investment and wealth management.”About JF SmartInvest Holdings Ltd (Stock Code: 9636)JF SmartInvest Holdings Ltd is a new generation stock investment assistant. The Company is engaged in the provision of equity investment instruments, securities investment advisory, investor education and other services to individual investors. The products include stock quote software, the AI Stock Machine, Stock Navigator, Super Investor and Jiuyao Stocks. The Company adopts the technology + investment research model, develops JF Robo-Advisor, FinSphere Agent, FinSphere Report and other products based on artificial intelligence (AI) and big data technology, which are applied to the industry in terms of innovative practice and scenario application.For enquiries, please contact:Financial PR (HK) LimitedEmail: ir@financialpr.hkTel: 852 2610 0846Fax: 852 2610 0842 Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com

SINGAPORE, Mar 27, 2026 - (ACN Newswire) - Choosing where to place your savings in Singapore is an important financial decision that requires careful consideration. With many banks offering different types of accounts, it is easy to get confused. However, picking the right one is the first step to reaching your financial goals, whether you are saving for a dream wedding, a new home, or a retirement fund.The good news is that you no longer need to spend a whole afternoon waiting at a bank branch. You can now open a bank account online in just a few minutes using your phone or computer. Here is a simple guide to help you choose the best account for your needs in 2026.Identify Your Financial HabitsBefore focusing on interest rates, consider how you manage your money on a daily basis. Savings accounts in Singapore usually fall into two categories:The Active Saver: These accounts give you high interest rates, but you have to make a few mandatory transactions each month. Usually, you need to credit your salary and spend a set amount on your credit card.The Passive Saver: These accounts help you earn bonus interest just for keeping your money in the account and letting it grow. You do not need to worry about credit card spending or paying bills.Compare Interest RatesBefore opening a bank account online, make sure you compare the interest rates. Many basic accounts offer low interest rates. To make your money grow, you should look for bonus interest.For example, a high-interest account can offer between 2% and 5% depending on the rules you follow. If you have SGD 50,000, the difference between a basic account and a high-interest one could be hundreds of dollars in extra cash every year. Always check the effective interest rate, which tells you the real amount you will earn after all the levels are counted.Look for Welcome PromotionsBanks in Singapore are always competing for your business. When you open a bank account online, you can often grab a welcome gift, such as cash credits or rewards. These promotions are a great way to get a head start on your savings. Just make sure to check the dates, as many of these flash deals only last for a few months.Check the Fees and MinimumsEven a great account can lose you money if you are not careful about fees. Before you sign up, check for these three things:Minimum balance: Most accounts require maintaining a certain amount of money in the account at all times. If the balance drops below this limit, the bank may charge you a monthly fee.Initial deposit: Some accounts require at least SGD 1,000 to get started.ATM access: Make sure the bank has plenty of ATMs near your home or office so you do not get charged for using the machine of another bank.Open an Account OnlineOnce you have picked the right account, the final step is to fill out your application. In Singapore, you can use Singpass MyInfo to fill out your application automatically.When you open a bank account online, your details, such as your NRIC, address, and income, are pulled directly from the government database, thus reducing paperwork. Most accounts are approved almost instantly, and you can start using your new digital card right away.Final ThoughtsChoosing a savings account is not just about finding the highest interest rate. It is about finding the one that fits how you live. If you are a busy professional who already uses a credit card, an active account is perfect. If you just want to set your money aside and forget it, a passive account is better.By taking 10 minutes to compare your options today, you can ensure that every dollar you earn works as hard as you do.Disclaimer: This article is for general information only and does not have any regard to the specific investment objectives, financial situation and particular needs of any specific person. The views expressed in this article are solely those of the author. This article shall not be regarded as an offer, recommendation, solicitation or advice. You may wish to consult your own professional advisers about this article, in particular, a financial professional before making financial decisions. Any past events, trends and/or performance referred to in this article may not necessarily be indicative of future events, trends or performance. This article is based on certain assumptions and reflects prevailing conditions as at the time of publication, which are subject to change at any time without notice. The author and publisher of this article as well as any other parties associated with this article make no representation or warranty of any kind, whether express, implied or statutory, in respect of this article and accept no liability or responsibility for the completeness or accuracy of this article or any error, inaccuracy or omission relating to this article and/or any consequence, injury, loss or damage howsoever suffered by any person relating to this article, in particular, arising from any reliance by any person on this article. Publishers or platforms may be compensated for access to third party websites.Contact Information:Name: Sonakshi MurzeEmail: Sonakshi.murze@iquanti.comJob Title: ManagerSOURCE: iQuanti Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com

- Annual sales of HuaTangNing exceeded 4 million packs, a year-on-year increase of 91%, with revenues reaching RMB 492.9 million, a year-on-year increase of 93%, marking outstanding results from the Company’s fully independent commercialization operation.- Delivered record financial performance, with profit before tax reaching RMB 1,106.4 million; maintained a robust bank balance and cash position of RMB 1,092.3 million at year-end, laying a solid foundation for sustainable operations and growth.- Gross margins rose to 56.9%, and selling expenses as a percentage of revenue were optimized to 33.6% from 59.9%, significantly enhancing profitability.- HuaTangNing renewed its listing in the new National Reimbursement Drug List (NRDL) at the same price in 2025 for the calendar years 2026 and 2027, reaffirming its clinical and innovative value.- With the approval of PTE, market exclusivity in China granted another 5 years to April 2034, further strengthening commercial certainty.- Dorzagliatin was approved for commercialization in Hong Kong as HYHOMSIS®, accelerating its global expansion toward South-East Asia.- Multiple real-world evidence published to demonstrate therapeutic advantage of dorzagliatin.- Continuous expansion of therapeutic potential of glucose homeostasis and initiation of new first-in-disease indications study covering diabetes prevention, rare diseases, mild cognition impairment and frailty.SHANGHAI, Mar 27, 2026 - (ACN Newswire) – Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552) announces the audited consolidated results of the Company and its subsidiaries for the year ended December 31, 2025 (the “Reporting Period”). During the Reporting Period, the commercialization of HuaTangNing (dorzagliatin tablets), the Company’s core product – the global first-in-class innovative anti-diabetes medicine, glucokinase activator (GKA) – advanced comprehensively across all fronts, the Company’s independent commercialization team was efficiently and seamlessly established in its first year of operations, the Company’s R&D pipeline continued to be enriched, and the Company’s financial performance achieved a historic breakthrough, successfully entering a new stage of profitability, injecting strong momentum into the innovative development of the global diabetes treatment field.Dr. Li CHEN, Founder and CEO of Hua Medicine, stated: “2025 is a remarkable year in the commercialization operation of Hua Medicine. The Company has successfully advanced from R&D to commercialization driven organization and achieved the fully independent capacity in commercialization of global first in class novel glucose homeostasis regulator HuaTangNing. With strong market execution and product competitiveness, we have achieved nearly triple-digit growth in sales volume and revenue over 2024 when the commercialization was farmed out to sales and marketing partners. At the same time, the Company has made key progress in global market expansion through registration of drozagliatin in Hong Kong and position it toward 700 M population in south-east Asia. We continue to expand the clinical application of glucose homeostasis regulation technology and engage in new indications such as early-stage Alzheimer’s disease and Frailty. The first-in-disease efforts in GCK-MODY and Frailty set the new innovation course of Hua Medicine in the next 5 years.” Business Highlights and Operational Progress- Fully Powered Commercialization, Historic Breakthrough in ProfitabilityOn January 1, 2025, the Company assumed full responsibility for the commercialization of HuaTangNing, allowing the company to consolidate both operational and strategic control over market execution in China. The Company successfully built a professional sales team covering 10 sales regions around the country, focusing on marketing, medical affairs and commercial operation. Through an AI-empowered digital commercialization platform, operational efficiency and sales productivity were greatly enhanced, injecting new vitality into the Company’s commercial development.Reimbursement coverage under the NRDL has significantly increased accessibility, especially in Tier 2 and Tier 3 hospitals, and played a critical role in accelerating patient adoption. Since its launch in October 2022, HuaTangNing has been prescribed to over 500,000 patients through 3,000+ hospitals, community centers, pharmacies and online channels.Sales performance exceeded expectations, with 4.011 million packs of HuaTangNing sold during the reporting period, representing a 91% increase over the fiscal year 2024. This growth was achieved at the same price for both periods, underscoring strong demand and successful execution of Hua’s commercial strategy.In terms of profitability, the Company’s gross profit reached approximately RMB280.4 million, a year-on-year increase of 125%. Thanks to expanded production scale and optimized manufacturing processes, the Company’s gross margin improved to 56.9%, increasing by 8.2 percentage points as compared to 48.7% for the year of 2024. Selling expenses increased only by RMB12.3 million to RMB165.5 million, reflecting a significant positive trend towards profitability when our selling expenses in the 2025 fiscal year represents only 33.6% of revenue, whereas in the 2024 fiscal year, our selling expenses represented approximately 59.9% of revenue. In fiscal year 2025, our commercialization efforts achieved profits of approximately RMB114.9 million (as defined by gross profits less selling expenses). Although we expect to continue to increase personnel to our commercialization team, we expect this profitability trend in our commercial operations in mainland China to continue.Following the termination of the collaboration with Bayer at the end of 2024, dorzagliatin achieved a record-high sales volume. Profit before tax increased to RMB1,106.4 million for the fiscal year 2025. We ended fiscal year 2025 with a cash position of approximately RMB1,092.3 million.- Accelerated Global Layout, Strengthened Core Rights and InterestsThe Company took a key step in global expansion. On February 27, 2026, dorzagliatin (trade name: MYHOMSIS®, was successfully approved for marketing by the Hong Kong regulatory authority. The Company plans to officially launch the product in the Hong Kong market by the middle of 2026 and further expand to Asian regions. In addition, the Company submitted a new drug registration application in Macau in 2025.The Company also made new progress in intellectual property protection. In February 2026, the patent term extension (PTE) application for dorzagliatin was formally approved by the China National Intellectual Property Administration, thereby the core patent protection period of dorzagliatin extended to April 2034 and an additional 5-year market exclusivity obtained, which provides a strong guarantee for the product’s long-term market competition.In 2025, dorzagliatin was recognized as national innovation and an effective therapy for chronic diseases by the regulatory authorities in China. Accordingly, the same NRDL price was offered for the calendar years 2026 and 2027. Reimbursement coverage under the NRDL has significantly increased accessibility, especially in Tier 2 and Tier 3 hospitals, and played a critical role in accelerating patient adoption. The Company will continue to safeguard the product’s market competitiveness and patient accessibility and accelerate the popularization of the drug among patients.- Advancement of Real-World Studies, Continuous Validation of Clinical ValueReal-world evidence (RWE) studies continue to corroborate the key role of dorzagliatin in improving glucose-dependent pancreatic islet secretion function, and demonstrate its efficacy in diabetes prevention, remission, and delaying or preventing diabetes complications.The RWE study sponsored by Hua Medicine HMM0701 with 380 T2D patients was fully enrolled in 2025. The interim analysis, as reported at the 2025 American Diabetes Association (ADA), showed that 86% of such patients were taking two or more antidiabetic drugs and 41% of such patients were using insulin. After a 6-month treatment, a significant improvement of glycemic control was observed with HbA1c reduction from 8.1% to 7.3% with the mean time-in-range (TIR) levels increasing to over 70%. Thus far, the studies have demonstrated that when dorzagliatin is administered in combination with other antidiabetic drugs, such patients have experienced significantly improved post-meal glucose levels and improved β-cell function.Separately, a mechanistic study with dorzagliatin (employing double-tracer measurement) was conducted in the United States to provide scientific evidence of hepatic glycogen formation in T2D patients with an average of 17 years of diagnosed diabetes. In this study, patients were treated with dorzagliatin twice daily for 6 weeks. The results showed that dorzagliatin increased direct glucose flux to hepatic glycogen implying the improvement of restoration of hepatic Glucokinase (GK) function. Together with the clinical research data that dorzagliatin improves early phase insulin release and GLP-1 secretion, recovery of hepatic glycogen synthesis in T2D patients offers an important path in controlling post-meal glucose excursion and provides a unique opportunity in controlling diabetes complications, such as diabetes kidney diseases and mild cognition impairment.The RWE sponsored by Hua Medicine (HMM0601) has completed clinical trials with over 2,000 subjects, with average diabetes duration of 7.9 years and above 30% having disease duration more than 10 years. The initial results suggest that dorzagliatin is safe and well tolerated in Chinese T2DM patients. There were no new adverse effects observed in the study and the incident rate remains as low as what was observed in Phase III clinical trials. Patient adherence was generally high, with a mean adherence rate of approximately 95%. In this study, 80% of the participants have used one or more oral anti-diabetes medicine, and 20% used insulin. Dorzagliatin demonstrated good efficacy and safety not only in the overall population but also in elderly, obese, and hyperglycemic patient populations, whether used as monotherapy or in combination with metformin, SGLT2 inhibitors, insulin, and other medications. The topline results will be reported at the 2026 American Diabetes Association.- Deepened Clinical R&D, Continuous Expansion of New IndicationsNew Indication for Dorzagliatin – MODY-2 Patients.Medical experts in mainland China and Hong Kong have conducted independent clinical and preclinical studies of dorzagliatin for MODY-2 treatment. MODY-2, also called GCK-MODY, is a monogenic disease in which patients have a genetic defect of glucokinase gene (GCK) which results in elevated blood glucose and significant reduction of the second phase insulin secretion. The population of GCK-MODY patients is approximately 1.7 million in China. These patients are diagnosed with diabetes at a young age and represent an unmet medical need given that currently available medications are not effective. In clinical studies with MODY-2 patients, China investigators have reported that dorzagliatin is effective in reducing blood glucose levels to normal levels in MODY-2 patients who previously failed to manage their elevated blood glucose levels when treated with metformin, TZD, DPP-IV inhibitors, and SGLT-2 inhibitors. Additional results demonstrated that a single dose of dorzagliatin improved overall glucose sensitivity and second phase insulin secretion significantly in GCK-MODY patients, suggesting a unique mechanism of action of dorzagliatin to regulate GLP-1 secretion. Based on such results, Hua Medicine has communicated and reached a consensus with the CDE at NMPA to file the IND submission of dorzagliatin for MODY-2 patients in 2026.Dorzagliatin for Diabetes Prevention.Prevention of diabetes is an important focus at Hua Medicine. There are approximately 1.12 billion people living with prediabetes worldwide. We have initiated SENSITIZE 3 clinical study in Hong Kong in pre-diabetic (IGT) subjects and in early diabetes patients. These studies represent first-in-disease studies. In this double-blinded placebo-controlled study, we will evaluate the blood glucose management and pancreatic function under IVGTT and OGTT conditions to better define the clinical treatment baseline and endpoints. We expect to complete this study in 2026 and explore the opportunity to file IND applications of dorzagliatin for diabetes prevention in China and Asian Pacific regions thereafter. Dorzagliatin for Neurodegenerative Diseases.MCI shows approximately 15.5% prevalence among elderly people in China and approximately 22% in the US, and is common in T2D patients with a 45% incidence rate. The development of dorzagliatin for neurodegenerative disease is a new focus in our drug discovery efforts. Through the Genome-Wide Association Study (GWAS) and Mendelian Randomization (MR) study, we have realized the important role of GCK gene activation in the prevention of memory loss and cognitive impairment in humans. It has also come to our attention that post-meal glucose excursion is closely related to Alzheimer disease and dementia. The bio-energy balance in the brain is largely dependent on the glucose homeostasis control in the peripheral organ and the neural network communication in the central and peripheral system via spatial temporal management. Impaired glucose homeostasis and diabetes conditions result in a reduction of glucose transporter expression and insulin receptor expression in the brain, which can be prevented by low dose dorzagliatin. We have realized the potential of dorzagliatin in the treatment of mild cognitive impairment (MCI) and will initiate these first-in-disease clinical studies in the future.Dorzagliatin for Frailty.Frailty is an age-related geriatric syndrome characterized by reduced tolerance to internal and external stressors. Approximately 17% of Americans and 11% of Asians over the age of 50 suffer from frailty, while pre-frailty affects roughly 50% and 47% of these populations, respectively. It is not a single-organ disease, but the consequence of dysregulated multisystem homeostasis. Genetic evidence supports the causal effects of glucokinase (GK) activation on lowering frailty risk. We plan to initiate clinical studies in the future to advance dorzagliatin’s application in frailty.Development of combination therapy for diabetes and complications.Dorzagliatin rescues pancreatic function in glucose insulin secretion and GLP-1 secretion, as evidenced by clinical and basic research results. It also improves hepatic insulin sensitivity and reduces hepatic insulin resistance through recovery of hepatic glycogen synthesis in T2D patients. The combination of dorzagliatin with DPP-IV inhibitors, SGLT-2 inhibitors, and GLP-1 agonists have demonstrated effective regulation of lipid metabolism. Studies in combination with anticancer PI3K inhibitors have also offered unique benefits for glucose homeostasis management.- Diversified Product Pipeline, Innovative Layout for Future GrowthHua Medicine continues to enrich its pipeline layout based on core products. The Company has accelerated the R&D of a fixed-dose combination (FDC) of dorzagliatin and metformin as a twice-daily therapy for Type 2 diabetes patients with inadequate glycemic control on metformin alone, to further improve patient medication compliance. The product is supported by the strong results of the loose-dose combination in both Phase III clinical trials and real-world use. The Company has submitted an IND application to NMPA, and the GMP commercial manufacturing process has been successfully carried out, preparing for the pivotal bioequivalence study for NDA filing in 2027. Clinical studies have shown that the combination of dorzagliatin and metformin can better control blood glucose, reduce postprandial blood glucose and improve fasting blood glucose, providing new clinical value for optimizing blood glucose homeostasis endpoints.We have advanced our 2nd generation GKA as a once daily therapy for patients with obesity, leveraging dorzagliatin effects in improved glucose-stimulated GLP-1 secretion in the pancreas and in the intestine. The MAD study of the 2nd generation GKA was initiated in the United States with first-patient-in in December 2025, and we expect to report topline data by the middle of 2026.Meanwhile, the Company is also exploring combination therapy regimens of dorzagliatin with GLP-1 receptor agonists, SGLT-2 inhibitors and other drugs. In a recently published clinical trial in China, researchers reported the superior benefits of our dorzagliatin in combination with semaglutide as compared to semaglutide alone in a 12-week study. The combination group showed superior results across several key measures, including glycemic control, bodyweight related indicators and β-cell function.Financial Summary- Revenue generated by the Company was approximately RMB 492.9 million from the sale of approximately 4.011 million packs of HuaTangNing, increases of approximately 93% and 91% respectively, as compared with the year ended December 31, 2024.- Gross profit generated by the Company for the year ended December 31, 2025, was approximately RMB280.4 million, representing an increase of approximately 125%, as compared with the year ended December 31, 2024, and gross margins rose to 56.9%.- Profit before tax increased by approximately 542% to approximately RMB1,106.4 million for the year ended December 31, 2025, as compared with the year ended December 31, 2024.- Bank balances and cash position was approximately RMB1,092.3 million as of December 31, 2025.- Expenditures incurred by the Company for the year ended December 31, 2025, were approximately RMB433.4 million.Forward-Looking StatementsThis document contains statements regarding Hua Medicine's and its products' future expectations, plans and prospects. Such forward-looking statements relate only to events or information as of the date on which the statements are made in this document and are subject to change in light of future developments. Except as required by law, the Company shall not be obligated to update or publicly revise any forward-looking statements or unforeseen events after the date of such statements, whether as a result of new information, future events or other circumstances. Please read this document carefully and understand that actual future performance or results of the Company may differ materially from expectations due to various risks, uncertainties or other statutory requirements.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment. In February 2026, dorzagliatin (Trade name: MYHOMSIS®,) was approved for marketing by the Pharmaceutical Services of the Department of Health of the Government of the Hong Kong Special Administrative Region of China.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsEmail: ir@huamedicine.comMediaEmail: pr@huamedicine.com Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 27, 2026 - (ACN Newswire) – 26 March, Unisound (09678.HK) announced its audited annual results for the year ended December 31, 2025. As the Company's first annual results announcement since listing, it underscores strong growth momentum and continued improvement in its financial profile.Revenue Mix Continues to Improve, with Faster Growth in H2For the full year of 2025, Unisound achieved total revenue of $175 million, representing a year-on-year (YoY) increase of 29%. Revenue in the second half of the year increased by 33% YoY to $117 million.It is worth noting that the Company's large language model (LLM) business generated a full-year revenue of $88.43 million, surging by over 10 times YoY. In particular, this business contributed approximately $72.49 million in H2 revenue, five times the level recorded in H1, demonstrating a compelling capacity for large-scale commercial application.Losses Narrowed Significantly, Making the Path to Profitability Increasingly ClearAlongside the rapid revenue growth, the Company's losses improved markedly. In the second half of 2025, the Company's net loss narrowed by 84% YoY, and its adjusted loss narrowed by 92% YoY, approaching break-even. This reflects the Company's ongoing improvements in cost control and operational efficiency.Simultaneously, some of the Company's operating metrics saw marked improvement. The adjusted expense ratio declined significantly by 10 percentage points YoY, while selling expenses decreased rather than increased and accounted for only 5.4%, highlighting a clear improvement in cost-to-efficiency ratio. In 2025, revenue per employee reached $365,300, up 25% YoY from $292,900 in 2024. Employee productivity continued to lead the industry, clearly underscoring the Company's core strengths in technology-driven, lean operations.Dual-Engine Strategy Gains Traction, with AI in Healthcare and AI in Daily Life Advancing in TandemIn 2025, driven by both technological breakthroughs and policy tailwinds, global demand for AI continued to rise. Unisound adhered to its "Strong Foundation Model + Deep Application" strategy, continued to strengthen its multimodal technology foundation, and drove the continuous elevation of the global influence of its proprietary large model matrix in fields such as healthcare, speech, and OCR.On the commercialization front, the Company leveraged its AI-native organization to accelerate business execution, and its dual-engine strategy in AI in Healthcare and AI in Daily Life delivered notable results. During the reporting period:The AI in Daily Life business achieved revenue of $140 million, a YoY increase of 30.8%. Among this, the Transportation segment recorded nearly 40% YoY growth. At present, AI agent applications based on the Shanhai large model have been deployed in more than 10 cities, including Qingdao, Ningbo, Shenzhen and Nanning. In addition, cumulative AI chip shipments exceeded 110 million units, further validating the Company's scale capabilities in endpoint AI products.The AI in Healthcare business achieved revenue of $35.38 million, a YoY increase of 22.3%, with average revenue per customer growing by 53.2% YoY. In 2025, over 70% of the hospitals the Company collaborated with were tertiary hospitals, and more than one-third of customers had maintained continuous cooperation for over three years. The medical-record entry and generation products powered by the medical large model delivered a 10-fold YoY increase in full-annual medical record generation at a single campus of a leading Class III hospital. The commercial insurance AI agent platform recorded a 37-fold YoY increase in case processing volume. In deep cooperation with a leading insurance group, the expense control rate was effectively raised to approximately 20%, delivering more than $145 million in incremental cost management compared with traditional review methods, comprehensively empowering insurance institutions to refine their medical risk management operations.Continued R&D Investment Strengthens the Technology MoatTo consolidate its industry-leading position, the Company continued to invest heavily in R&D in 2025. Full-year R&D expenses exceeded $55.09 million, accounting for 75% of the Company's adjusted operating expenses, while R&D personnel accounted for 69% of the total workforce. This sustained investment drove breakthroughs across multiple technology areas. For example, in the MedBench 4.0 evaluation, the Company ranked first place in three technical paradigms: "Medical AI Agent," "Medical Large Language Model," and "Medical Multimodal Large Model," earning a "Triple Crown."Outlook: Deepening the Technological Foundation and Expanding Application BoundariesLooking ahead, Unisound will continue to deepen its "Strong Foundation Model + Deep Application" strategy. On the technological front, the Company will continue to increase strategic investment in foundational large models and strive to maintain a world-class level. On the application front, it will use the large-scale expansion of MaaS (Model-as-a-Service) and AI agents as its core growth engine, driving exponential growth in its AI in Daily Life and AI in Healthcare businesses. Meanwhile, the Company is actively exploring the establishment of a recurring revenue system through models such as API calls and Token-based billing, and regards opportunities in consumer-facing (C-end) products as a second growth curve to further expand its commercialization boundaries.Between Q2 and Q3 2026, Unisound will launch a native AI agent large model for programming and office applications, which is expected to double both intelligence density and token production efficiency. Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com

Financial HighlightsRMB 100 millionFor the 12 months ended 31 DecemberChange (%)20252024Revenue1566.111,776.64-11.85% Profit28.4265.53-56.64% Profit before Tax28.1665.95-57.30% Gross Profit194.95222.47-12.37% Gross Profit Margin12.45%12.52%-0.07pct Net Profit13.3741.95-68.12% Net Profit Attributable to Shareholders and Other Equity Holders2.2129.72-92.57% Net cash flows from operating activities 185.1492.6499.86% Dividend per share (RMB/share, tax inclusive)RMB 0.179RMB 0.176N/A Total dividend payout9.399.45-0.60% Performance Highlights1. Solid operating core segments with resilient high-quality development: In 2025, the Group achieved revenue of RMB 156.611 billion, net profit of RMB 1.337 billion, and maintained a gross profit margin of 12.45%, with a balanced domestic and overseas revenue structure.2. Dual improvement in cash flow and financial quality, with significantly enhanced risk resilience: Net cash flows from operating activities increased substantially by 99.86% to RMB 18.514 billion, while the cash and cash equivalents as of the end of the Year reached RMB 24.3 billion; the scale of interest-bearing debt decreased by RMB 4.7 billion year-on-year (“YoY”) to RMB 34.4 billion, and net interest expenses decreased by approximately RMB 730 million YoY, with the financial structure continuing to be optimized.3. Cash dividends and share buybacks implemented in parallel to reward investors: The Group proposes a cash dividend of RMB 0.179 per share (tax inclusive) for 2025. Together with multiple rounds of H-share and A-share buyback plans launched during the Year, the total proposed dividend and completed buybacks for 2025 amounted to RMB 1.852 billion.4. Significant improvement in profitability of energy-related businesses, becoming a key growth driver of the Group: Net profit of the offshore engineering segment and the financial and asset management segment (primarily drilling platform leasing) increased by approximately RMB 1.212 billion in total, while the energy, chemical and liquid food equipment segment increased by RMB 308 million. Among them, the gross profit margin of the offshore engineering segment increased significantly by 5.72 percentage points to 14.83%. Orders on hand for offshore engineering and energy, chemical and liquid food equipment reached US$5.09 billion and RMB 29.75 billion, respectively, with certain shipyards’ production schedules extending to 2030.5. Logistics-related businesses continued to serve as the Group’s “ballast stone”: During the Year, businesses such as container manufacturing and road transportation vehicles were affected by exchange rate fluctuations and cyclical changes, resulting in pressure on gross profit margins and profitability. However, the core segments remained solid, and the Group’s competitive advantages in the industry continued to be consolidated. Core products such as standard dry containers, reefer containers, tank containers and semi-trailers have maintained the world’s No.1 position for many consecutive years.6. Breakthroughs in both technology and orders in key businesses, with competitiveness highly recognised: In the high-end offshore engineering equipment sector, CIMC Raffles successfully developed the most complex products in the offshore industry, including FPSO/FLNG, becoming the only enterprise in China with dual-project EPCI general contracting capabilities; in the modular data center sector, the Group providing technical and manufacturing delivery services of prefabrication data center to industry customers exceeding 300MW, leading new transformation in computing power infrastructure.HONG KONG, Mar 26, 2026 - (ACN Newswire) – China International Marine Containers (Group) Co., Ltd. (“CIMC Group” or the “Group”, stock code: 000039.SZ/02039.HK) is pleased to announce the audited annual results for the 12 months ended 31 December 2025 (the “Year”).The Group’s management stated, “In 2025, profound global changes unseen in a century accelerated, and the global economy demonstrated resilience amid volatility. Positioned in an era of both opportunities and challenges, the Group closely adhered to the strategic theme of “accelerating the construction of new growth drivers and focusing on promoting high-quality development”. While stabilising its operating fundamentals, the Group further deepened its forward-looking strategic layout in the energy business and achieved fruitful results. For the year of 2025, the Group recorded revenue of RMB 156.61 billion and net profit of RMB 1.34 billion. Cash flows from operating activities increased significantly by 99.9% to RMB 18.51 billion, with the asset structure continuously optimized and risk resilience further enhanced.”In particular, to sincerely reward investors, CIMC Group proposes to distribute a cash dividend of RMB 0.179 per share (tax inclusive) to all shareholders for 2025, amounting to a total proposed cash dividend of RMB 939 million (tax inclusive). Meanwhile, the Group implemented share buybacks totalling RMB 913 million during 2025, bringing the combined total to RMB 1.852 billion.Segments Results (RMB 100 million)2025 Business indicatorsRevenueAs % of the total revenueGross profitAs % of the gross profitGross profit marginNet profitContainer manufacturing430.0927.46%57.5529.52%13.38%18.82Road transportationvehicles201.7812.88%32.0616.45%15.89%9.27Energy, chemical, and liquid food equipment271.9217.36%40.2420.64%14.80%10.40Offshore engineering179.3811.45%26.6013.65%14.83%10.57Logistics services267.9317.11%16.708.57%6.23%3.64Airport facilities and logistics equipment/fire safety and rescue equipment76.194.86%15.147.76%19.87%2.64Total of major segments1427.2991.12%188.2996.59%13.19%55.34Core Business Performance1. In logistics field:In the container manufacturing business, during the Year, despite negative supply chain factors such as U.S. tariff policies and geopolitical conflicts, global merchandise trade demonstrated strong resilience. Intra-regional trade, Asia-Europe routes and emerging market routes became the main drivers of incremental growth. Meanwhile, factors such as detours around the Red Sea, port congestion, environmental requirements in shipping and increasing complexity of trade routes reduced transportation efficiency, structurally boosting underlying demand and pushing the global container fleet into a new structural phase. As a result, overall demand for new containers in 2025 remained at a relatively high level, exceeding the average of the past decade. During the Year, the production and sales volume of the Group’s container manufacturing business declined YoY, in line with overall industry expectations, but the Group maintained its global No.1 position. Accumulated sales volume of dry cargo containers reached 2,224,900 TEUs (2024: 3,433,600 TEUs), representing a YoY decrease of 35.2%. Accumulated sales volume of reefer containers reached 208,200 TEUs (same period last year: 138,600 TEUs), representing a YoY increase of 50.2%. During the Year, the container manufacturing segment recorded revenue of RMB 43.009 billion, net profit of RMB 1.882 billion, and a slight decline in gross profit margin to 13.38%.In the logistics services business, during the Year, the segment recorded revenue of RMB 26.793 billion, representing a YoY decrease of 14.64%, and net profit of RMB 364 million, representing a YoY decrease of 16.65%, in line with industry trends. CIMC Wetrans actively adjusted its business structure and integrated resources. During the Year, self-sourced cargo volume increased by 6% YoY, while second-hand container trading and warehousing distribution in port logistics reached record highs. The industry logistics business focused on key sectors such as new energy, automotive and engineering projects to consolidate its niche advantages. In 2025, CIMC Wetrans ranked among the top five for three consecutive years in the “Comprehensive List of Freight Forwarding and Logistics Enterprises” published by the China International Logistics and Freight Forwarding Association.In the road transport vehicles business, during the Year, CIMC Vehicles recorded revenue of RMB 20.178 billion, representing a YoY decrease of 3.91%, and net profit of RMB 927 million, representing a YoY decrease of 14.29%. In the domestic market, the “Star-Chained Plan” reshaped the organisational and operational model, with revenue from the China semi-trailer business increasing by 14.65% YoY and gross profit margin increasing by 3.3%YoY. In overseas markets, the Global South markets maintained high-quality growth, with revenue reaching RMB 3.09 billion during the Reporting Period, representing a YoY increase of 17.7%, sales volume increasing by 29.1% YoY, and gross profit margin increasing by 1.3 percentage points YoY.The DTB business achieved steady growth in both sales volume and revenue, with a total of 28,570 units of mounted equipment products delivered, generating total revenue of RMB 3.184 billion, representing a YoY increase of 4.97%, with further improvement in market share of core products. Meanwhile, the Group continued to actively expand R&D and sales of new energy products, comprehensively building the EV-RT ecosystem and advancing the strategic development of pure electric tractors and trailers.In the airport facilities and logistics equipment/fire safety and rescue equipment, benefiting from the release and delivery of high-quality orders, the segment recorded revenue of RMB 7.619 billion during the Year, representing a YoY increase of 5.92%, and net profit of RMB 264 million. Airport equipment successfully delivered smart boarding bridges projects for Xi’an Xianyang International Airport, Antalya Airport in Türkiye and Lanzhou Airport, and secured major projects including Phase II of Nanning Airport and corridor projects at Hangzhou Airport T2 and T4 with its independently-developed innovative prefabricated fixed bridge solutions. Logistics equipment delivered automated three-dimensional warehouse systems for supporting the petrochemical and refining integration project in China. The fire safety and rescue equipment business advanced the overseas expansion of domestically manufactured products while focusing on frontier areas such as smart fire safety and unmanned fire trucks.2. In the Energy FieldIn the energy, chemical, and liquid food equipment business, the segment recorded revenue of RMB 27.192 billion, representing a YoY increase of 6.31%, and net profit increased significantly by 42.15% to RMB 1.040 billion. Among which, CIMC Enric recorded revenue of RMB 26.326 billion, representing a y YoY increase of 6.3%.Specifically, the clean energy segment advanced both offshore and onshore businesses, maintaining leading market share in key equipment such as high-pressure and cryogenic equipment, while capturing growth opportunities in natural gas applications in water and land transportation and power generation, and actively expanding into emerging markets for special industrial gas equipment in high-tech industries. In 2025, the segment secured new orders of RMB 22.229 billion, a record high. Among these, orders on hand for offshore clean energy-related business exceeded RMB 19 billion as of the end of 2025, with shipbuilding schedules extending to 2028. During the Year, the second coke oven gas comprehensive utilisation project — Linggang Phase I project — was successfully put into operation, and China’s first domestic mass-production bio-methanol (green methanol) project of CIMC Enric was completed and commenced operation. The chemical and environmental segment maintained its leading market share, while the medical equipment components and after-sales service businesses achieved steady growth. As of the end of 2025, orders on hand increased by 36.27% YoY to RMB 1.276 billion, providing strong support for future development. The liquid food segment maintained stable profitability, with gross profit margin increasing to 21.7% YoY.In the offshore engineering business, the Group’s core operating entity, CIMC Raffles, successfully achieved a strategic transformation from “manufacturing-led” to integrated “design + construction + integration” services, maintaining a leading position in the domestic market and emerging as an important new force in the international offshore engineering market. During the Reporting Period, the segment recorded revenue of RMB 17.938 billion, representing a YoY increase of 8.35%, and net profit of RMB 1.057 billion, becoming the Group’s second-largest profit contributor. Benefiting from the recovery of the global offshore engineering market, demand for high-end oil and gas equipment represented by FPSO/FLNG remained strong, while the industry accelerated its transition toward green and intelligent development, driving steady growth in new energy equipment orders. During the year, the Group secured new contract orders of US$1.20 billion, including 12+8 container feeder vessels, 2 offshore engineering special vessels and other module orders. As of the end of 2025, the accumulated value of orders on hand reached US$5.09 billion, with orders for oil & gas and special vessel accounting for approximately 70% and 30%, respectively. The Longkou base has scheduled production through to 2030.In the offshore engineering asset operation and management business, the Group continued to leverage its existing project experience and business capabilities, enhancing asset utilisation through its strong offshore platform operation and management capabilities. During the Reporting Period, the sixth-generation semi-submersible drilling platform “Deepsea Yantai” completed lease renewal, the ultra-deepwater semi-submersible drilling platform “Blue Whale No.1” signed a new lease with an international client, and the semi-submersible lifting/life platform “Blue Gretha (formerly Huadian CIMC 01)” also secured a new lease with an international client. Other platforms actively participated in market tenders to explore opportunities for asset disposal and leasing. During the Reporting Period, the average daily lease rate of semi-submersible and jack-up drilling platforms both recorded year-on-year increases.Future Development and ProspectsThe Group’s management stated, “The year 2026 marks the beginning of the ‘15th Five-Year Plan’. Starting from a newly upgraded brand identity, the Group will closely focus on ‘consolidating foundations, driving innovation, improving quality and efficiency’, and adopt a more proactive strategic approach to foster new opportunities and open new horizons amid complex changes, striving to build a ‘“becoming a high quality and trustworthy world-class multimodal transport enterprise.”About China International Marine Containers (Group) Co., Ltd.The CIMC Group is a world-leading equipment and solution provider in the logistics and energy industries, with its industry clusters mainly covering the logistics and energy fields, continuously strengthening its leading market position. In the logistics field, the Group continues to adhere to container manufacturing as its core business, based on which it has incubated the road transportation vehicles business and the airport facilities and logistics equipment / fire safety and rescue equipment business, supplemented by the logistics services business and recycled load business, providing products and services in the professional logistics field. In the energy field, the Group is principally engaged in the energy, chemical and liquid food equipment business and the offshore engineering business. Meanwhile, the Group continues to develop emerging industries and possesses financial and asset management businesses that serve the Group itself. As a diversified multinational industrial group serving the global market, CIMC has over 300 member enterprises across Asia, North America, Europe, and Australia, with a total of four listed companies, and customers and sales networks covering more than 100 countries and regions worldwide. In 2025, the Group recorded revenue of RMB 156.6 billion, ranking 154th on the 2025 Fortune 500 China list. The Group has maintained the world’s No.1 position for many consecutive years in core products such as standard dry containers, reefer containers, tank containers and semi-trailers. For more information, please visit http://www.cimc.com/. Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com